Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports

Taxanes, including paclitaxel (PTX) and docetaxel (DOC), are poorly soluble in water due to their hydrophobic properties and thus, require solvents. However, use of these solvents has been associated with toxic responses, including a hypersensitivity reaction (HSR). Nanoparticle albumin-bound paclit...

Full description

Saved in:
Bibliographic Details
Published inOncology letters Vol. 6; no. 4; pp. 881 - 884
Main Authors KIMURA, KOSEI, TANAKA, SATORU, IWAMOTO, MITSUHIKO, FUJIOKA, HIROYA, TAKAHASHI, YUKO, SATO, NAYUKO, TERASAWA, RISA, TOMINAGA, TOMO, IKARI, AYANA, UCHIYAMA, KAZUHISA
Format Journal Article
LanguageEnglish
Published Greece D.A. Spandidos 01.10.2013
Spandidos Publications UK Ltd
Subjects
Breast cancer
Cancer therapies
Case reports
Chemotherapy
Cytotoxicity
Diabetes
Dyspnea
Endocrine therapy
Family medical history
hypersensitivity reactions
Metastasis
nab-paclitaxel
Nanoparticles
Neutropenia
Patients
Response rates
Solvents
Steroids
nab-paclitaxel
breast cancer
hypersensitivity reactions
Online AccessGet full text

Cover

More Information
Summary:Taxanes, including paclitaxel (PTX) and docetaxel (DOC), are poorly soluble in water due to their hydrophobic properties and thus, require solvents. However, use of these solvents has been associated with toxic responses, including a hypersensitivity reaction (HSR). Nanoparticle albumin-bound paclitaxel (nab-PTX) is a novel formulation of PTX, which allows reconstitution of the agent with a saline solution instead of solvents and administration without premedication for HSRs. The current study reports the safe administration of nab-PTX to four breast cancer patients considered clinically to have contraindications to PTX or DOC. Two of the patients had previously experienced HSRs to PTX or DOC and the other two patients had contraindications to steroids as a premedication for HSRs, since one patient suffered from diabetes and the other was a carrier of the hepatitis B virus. All 4 patients were safely administered nab-PTX. In conclusion, administration of nab-PTX appears to be effective for patients that have previously experienced HSRs to other taxanes or in those with contraindications to steroids.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2013.1471